Multiple myeloma: Clinical practice guidelines in oncology™

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Raymond L. Comenzo, Carlos M. De Castro, Benjamin Djulbegovic, Sherif Farag, Carol Ann Huff, Ruby Meredith, Jeffrey Schriber, Dennis Shrieve, Seema Singhal, Mitchell R. Smith, Keith Stockerl-Goldstein, Julie M. Vose, Donna Weber, Joachim Yahalom, Furhan Yunus

Research output: Contribution to journalArticle

Abstract

Although multiple myeloma is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. These guidelines prominently identify the clinical settings appropriate for treatment of patients on clinical research protocols.

Original languageEnglish (US)
Pages (from-to)118-147
Number of pages30
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number2
Publication statusPublished - Feb 2007
Externally publishedYes

    Fingerprint

Keywords

  • C-reactive protein
  • Combination chemotherapy
  • Cytogenetics
  • Immunomodulatory drugs
  • Multiple myeloma
  • NCCN Clinical Practice Guidelines
  • Primary amyloidosis
  • Proteosome inhibitor
  • Stem cell transplant
  • Waldenström's monoclonal protein

ASJC Scopus subject areas

  • Oncology

Cite this

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Comenzo, R. L., ... Yunus, F. (2007). Multiple myeloma: Clinical practice guidelines in oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 5(2), 118-147.